Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.41 USD | -4.87% | -5.96% | +32.69% |
May. 15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
May. 14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Financials (USD)
Sales 2024 * | 2.62M | Sales 2025 * | 27.84M | Capitalization | 41.45M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -10M | EV / Sales 2024 * | 15.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.49 x |
P/E ratio 2024 * |
-1.73
x | P/E ratio 2025 * |
-3.62
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.36% |
Latest transcript on Daré Bioscience, Inc.
1 day | -4.87% | ||
1 week | -5.96% | ||
1 month | +31.41% | ||
3 months | -25.44% | ||
6 months | +15.17% | ||
Current year | +32.69% |
Managers | Title | Age | Since |
---|---|---|---|
Sabrina Johnson
FOU | Founder | 57 | 14-12-31 |
Annie Thurman
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Jessica Hatheway
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robin Steele
BRD | Director/Board Member | 68 | 14-12-31 |
Cheryl Blanchard
BRD | Director/Board Member | 59 | 19-11-19 |
Chairman | 75 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.41 | -4.78% | 190,630 |
24-05-30 | 0.4306 | -8.38% | 406,825 |
24-05-29 | 0.47 | +15.17% | 1,227,652 |
24-05-28 | 0.4081 | -6.40% | 350,996 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.69% | 41.45M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- DARE Stock